Safe Surf Rated Back To Home Page Family Friendly Site

Positively Positive
- Living with HIV
Curriculum Vitae:
HIV / AIDS Involvements
  Biography   HIV/AIDS
News Archive
HIV/AIDS News Bradford McIntyre

Sumagen Canada Inc. Awarded Financial Contribution from the Government of Canada to support Human Clinical Trials for HIV/AIDS Vaccine (SAV001)

January 12, 2012 - London, Ontario CANADA - Sumagen Canada Inc. has been awarded a non-refundable financial contribution of up to $728,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support human clinical trials for our preventative HIV vaccine which is based on a genetically modified killed whole virus, SAV001. Sumagen Canada received approval from the United States Food and Drug Administration (FDA) in December 2011 to commence Phase I clinical trials.

The HIV vaccine (SAV001) holds tremendous promise, having already proven to stimulate strong immune responses in preliminary studies with no adverse effects or safety risks. It is the only HIV vaccine currently under development in Canada, and one of only a few in the world.

This financial assistance from NRC-IRAP under The Canadian HIV Technology Development (CHTD) Program and the Bill and Melinda Gates Foundation will assist Sumagen Canada to proceed more quickly to Phase I human clinical trials to test the safety of its SAV001 HIV/AIDS vaccine. The CHTD Program is part of a broader Canadian HIV Vaccine Initiative (CHVI) collaboration between the Government of Canada and the Bill and Melinda Gates Foundation. The SAV001 vaccine has the potential to save millions of lives around the world by preventing HIV infection. SAV001 is a vaccine that addresses one of the most tragic health crises affecting millions of people around the globe.

HIV/AIDS has killed more than 28 million people worldwide, and more than 35 million people currently live with the virus. Since the virus was characterized in 1983, there have been numerous trials through pharmaceutical companies and academic institutions around the world to develop vaccines; however, no commercialized vaccine has been developed to date. Other HIV vaccines evaluated through human clinical trials have focused on either one specific component of HIV or recombinant viruses carrying the HIV genes. SAV001 HIV vaccine is unique in that it uses a killed whole HIV-1, a genetically engineered vaccine.

Sumagen Co., Ltd., the parent company of Sumagen Canada, has committed substantial resources to this project since 2005 and is very pleased to have the support of NRC-IRAP and the Bill and Melinda Gates Foundation to move forward with the project. Sumagen is committed to continuing to grow its business in Canada and be part of the business community in London.


About Sumagen Canada
Located in The Stiller Centre for Technology Commercialization in Western’s Research Park in London, Ontario, Sumagen Canada was established in 2008 specifically to manage and support clinical development of SAV001 vaccine. Sumagen Canada is a subsidiary of Sumagen Co. Ltd., a Korean-based pharmaceutical venture company.

Media contact: Doris Hall, Office Manager, Sumagen Canada Inc. 519-858-5125,

"Reproduced with permission - Sumagen Canada Inc."


...positive attitudes are not simply 'moods'

Site Map

Contact Bradford McIntyre.

Web Design by Trevor Uksik

Copyright © 2003-2019 Bradford McIntyre. All rights reserved.